Results 251 to 260 of about 16,645 (269)

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Lancet, The, 2019
Pascal Vranckx, Marco Valgimigli, Thorsten Lewalter   +2 more
exaly  

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Lancet, The, 2016
Andreas Goette, JosÉ Luis Merino, Joris R De Groot   +2 more
exaly  

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

New England Journal of Medicine, 2018
Nick van Es, Peter Verhamme, Marc Carrier   +2 more
exaly  

Edoxaban-induced oesophagitis

European Heart Journal
openaire   +2 more sources

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

New England Journal of Medicine, 2013
Harry R Büller, Saskia Middeldorp, Peter Verhamme   +2 more
exaly  

Edoxaban versus Warfarin for Venous Thromboembolism

New England Journal of Medicine, 2014
openaire   +4 more sources

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Circulation, 2017
Anthony P Carnicelli, Raffaele De Caterina, Giulia Renda   +2 more
exaly  

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

American Heart Journal, 2010
Christian Ruff, Robert P Giugliano, Elliott M Antman   +2 more
exaly  

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

Thrombosis and Haemostasis, 2010
Stuart J Connolly, Jeffrey I Weitz
exaly  

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

Lancet Haematology,the, 2016
Nick van Es, Pantep Angchaisuksiri, Doyeun Oh   +2 more
exaly